Feb 3, 2021 | Securities Class Action Archive
Investigation Of Brookdale Senior Living Directors And Officers For Potential Breach Of Fiduciary Duty Claims – Brookdale Investors Who Have Held Their Stock Continuously Since At Least 2019 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating whether certain officers and/or directors of Brookdale Senior Living Inc. (“Brookdale” or the “Company”) (NYSE: BKD) breached their fiduciary duties to Brookdale and the Company’s shareholders.
The investigation concerns whether certain officers and/or directors of Brookdale, among other things, failed to disclose and/or made misleading statements regarding Brookdale’s business, operational, and legal profiles, including whether the Company intentionally underestimated data inputs to meet financial benchmarks.
If you have held Brookdale stock continuously since at least 2019 and wish to discuss Kehoe Law Firm’s investigation or have questions about your potential legal rights, please contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], [email protected], to learn more about the investigation or potential legal claims.
Feb 2, 2021 | Securities Class Action Archive
iRhythm Investors Who Have Suffered Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC) to determine whether the Company engaged in securities fraud or other unlawful business practices.
INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, iRHYTHM SECURITIES BETWEEN AUGUST 4, 2020 AND JANUARY 28, 2021, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $100,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT KEVIN CAULEY, DIRECTOR, BUSINESS DEVELOPMENT, (215) 792-6676, EXT. 802, [email protected], [email protected], [email protected], TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
On February 1, 2021, a class action lawsuit was filed against iRhythm in United States District Court, Northern District of California.
According to the class action complaint, throughout the Class Period, the iRhythm Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors. The iRhythm Defendants, allegedly, misrepresented and/or failed to disclose to investors that (1) iRhythm’s business would suffer as a result of the U.S. Centers for Medicare and Medicaid Services’ (“CMS”) rulemaking; (2) reimbursement rates would in fact plummet; (3) a lack of national pricing in the CMS rule and fee schedule would cause uncertainty and weakness in the Company’s business; and (4) as a result of the foregoing, the iRhythm Defendants’ public statements were materially false and misleading at all relevant times.
Jan 27, 2021 | Securities Class Action Archive
Bit Digital Investors Who Have Suffered Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Bit Digital, Inc. (“Bit Digital” or the “Company”) (NASDAQ: BTBT) to determine whether the Company engaged in securities fraud or other unlawful business practices.
BIT DIGITAL INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMPANY’S SECURITIES BETWEEN DECEMBER 21, 2020 AND JANUARY 8, 2021, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $100,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], [email protected], TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
On January 20, 2021, a class action lawsuit was filed against Bit Digital in United States District Court, Southern District of New York.
According to class action complaint, throughout the Class Period, the Bit Digital Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Allegedly, the Bit Digital Defendants failed to disclose to investors: (1) that Bit Digital overstated the extent of its bitcoin mining operation; and (2) as a result of the foregoing, the Bit Digital Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jan 8, 2021 | Antitrust
Have You Served As A Senior-Level Employee For Surgical Care Affiliates Or Its Competitors Between 2010 and 2017?
Kehoe Law Firm, P.C. is investigating class action claims on behalf of senior-level employees who worked for Surgical Care Affiliates or its competitors between 2010 and 2017.
On January 7, 2021, the U.S. Department of Justice issued a press release (“Health Care Company Indicted for Labor Market Collusion”), which, among other things, stated that “[a] federal grand jury returned a two-count indictment charging Surgical Care Affiliates LLC and its related entity (collectively SCA), which own and operate outpatient medical care centers across the country, for agreeing with competitors not to solicit senior-level employees, . . .. These are the Antitrust Division’s first charges in this ongoing investigation into employee allocation agreements.”
The indictment, according to the Department of Justice, further “. . . charges SCA with entering into and engaging in two separate bilateral conspiracies with other health care companies to suppress competition between them for the services of senior-level employees, in violation of the Sherman Act. Beginning at least as early as May 2010 and continuing until at least as late as October 2017, SCA conspired with a company based in Texas to allocate senior-level employees by agreeing not to solicit each other’s senior-level employees. Beginning at least as early as February 2012 and continuing until at least as late as July 2017, SCA separately conspired with a company based in Colorado to allocate senior-level employees through a similar non-solicitation agreement.”
If you served as a senior-level employee at Surgical Care Affiliates or one of its competitors between 2010 and 2017 and wish to discuss Kehoe Law Firm’s investigation or potential legal claims, please contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected].
Dec 19, 2020 | Securities Class Action Archive
Investors Of GoodRx Holdings With Significant Losses Encouraged To Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of GoodRx Holdings, Inc. (“GoodRx” or the “Company”) (NASDAQ: GDRX) to determine whether the Company engaged in securities fraud or other unlawful business practices.
INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE SECURITIES OF GOODRX BETWEEN SEPTEMBER 23, 2020 AND NOVEMBER 16, 2020, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], [email protected], TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
A class action lawsuit has been filed seeking to recover damages on behalf of GoodRx investors who purchased, or otherwise acquired, GoodRx securities during the Class Period and suffered losses.
According to the class action complaint, at the time of GoodRx’s September 2020 Initial Public Offering (“IPO”), unbeknownst to investors, Amazon.com, Inc. (“Amazon”) was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx.
The complaint alleges that the GoodRx Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given the GoodRx Defendants’ knowledge of Amazon’s intention to enter the online pharmaceutical business, and their misleading statements about GoodRx’s competitive position made contemporaneously with that knowledge, the GoodRx Defendants’ allegedly made materially false and/or misleading statements and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
The class action complaint alleges that on November 17, 2020, just weeks after GoodRx completed its IPO, Amazon announced two new pharmacy offerings, a Prime Rx plan and a discount card program, which, among other things, would compete directly with GoodRx’s platform by making it “simple for customers to compare prices and purchase medications for home delivery, all in one place.”
On this news, according to the complaint, the price of GoodRx common stock declined 23%, from $46.72 per share to $36.21 per share by the close of the market on November 17, 2020, erasing more than $4 billion of GoodRx’s market capitalization, thereby damaging GoodRx investors.
